Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
about
Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison PopulationExpert opinion on the treatment of patients with chronic hepatitis CPatient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational studyPredicting the probable outcome of treatment in HCV patients.HCV infected prisoners: should they be still considered a difficult to treat population?The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence researchGene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)Quality of life in hepatitis C.Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsEmerging therapies for hepatitis C virus.Instrumental support to facilitate hepatitis C treatment adherence: working around shortfalls in shared-care.A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion.Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion.The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion.Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin.Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation.Therapy outcome in patients with chronic hepatitis C: role of therapy supervision by expert hepatologists.Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
P2860
Q27473164-E203124A-1DA4-4955-8EE2-F233160BD7B2Q27489903-37FDAF11-2E74-42E0-B994-5DE0A173B6FDQ27490163-1DC62C13-A72F-4CEA-80FF-BC350992A505Q34409039-A45ACC0C-3CC3-4D68-9761-34DB9822245EQ34941459-F64C2A42-6B40-480F-8CA9-F1245B835A2BQ34996746-1CAF7C0F-89F0-47A5-8280-7EE6186F5E14Q35008754-4C8347B3-86B3-4409-864B-53FAED6D338FQ36373495-EB7D5AD2-80FC-4685-930A-D42A13089CE3Q36566758-86E36C0D-C6F0-45D7-B0DC-C79BBC4FFADFQ36843554-2C5F3FBC-FD71-468A-B765-4C34F47EE0BDQ37772514-5BEC164D-0E31-4E4F-B98A-2D4F1A7F30DEQ39163980-964D205A-8126-474F-8E3C-660A0A50980BQ40134402-9BA84D1B-183E-407C-AE9A-B7EE7B0C28FCQ40561879-F544766B-4FBB-4AE9-A91C-5D66E2D0D754Q40921653-6E504BF2-628D-4B5F-8A52-BCA8D4AE79B2Q41524400-EAFDEBF0-0115-45AD-A4AE-C37143BF83A2Q42984427-A462F82E-8BFB-4E9B-A9D7-ED4F54F9CDBFQ42998971-63D0DC4C-96AD-41EE-B1B3-2C3D5D2B6413Q43040033-07B0DAE2-0F70-42E8-8F4C-AD9A8DBCCEA7Q45364962-89AE57B5-E69F-4EE8-9666-6BA802F0C5B9Q46902016-3286080D-2A1E-4BBF-8440-41CB3F91D1D7Q50558649-AFCB27E7-02F6-4BEF-99A0-EE94B23DCA84
P2860
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@ast
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@en
type
label
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@ast
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@en
prefLabel
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@ast
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@en
P1476
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
@en
P2093
Brian P Mulhall
Zobair Younossi
P356
10.1097/01.MCG.0000145538.43865.72
P433
P577
2005-01-01T00:00:00Z